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CHAPTERl.GENERALINTRODUCTION 
Thesis organization 
This thesis is written using the alternate format described in the Graduate School 
Guidelines of Iowa State University. It includes a general introduction to the research 
problem, a literature review regarding the related background information on Campylobacter, 
two separate chapters concerning antibiotic resistance in Campylobacter, and a final chapter 
that summarizes the research and discusses our contributions to understanding the 
mechanisms of the antibiotic resistance in Campylobacter and to the prevention of antibiotic 
resistance in Campylobacter. The references cited throughout the text are located 
immediately after each chapter. 
Statement of the problem and research summary 
Campylobacter has emerged as a major gastroenteritis bacterial pathogen over the last 
three decades, with Campylobacter jejuni (C. jejuni) being responsible for the most of the 
infections caused by these organisms, followed by Campylobacter coli (C. coli). 
Fluoroquinolone (FQ) and macrolides are the two key drugs used for treatment of 
campylobacteriosis in humans. These two classes of antibiotics are also used regularly in 
farm animals for therapeutic and/or growth purposes in the US and around the world. 
However, the effectiveness of these antibiotics against Campylobacter has significantly 
reduced due to the development of resistance in Campylobacter isolates both from animals 
and humans. 
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The major mechanism responsible for FQ resistance in Campylobacter is spontaneous 
point mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene 
(encoding the A subunit of DNA gyrase). Multidrug efflux pump CmeABC is also described 
accountable for both acquired and intrinsic resistance to FQ in Campylobacter. These two 
mechanisms function synergistically to confer high level of FQ resistance in Campylobacter. 
In an attempt to reveal potential targets to reduce the incidence of FQ resistance, we 
investigated the role of the CmeABC on the emergence of FQ-resistance frequency in 
Campylobacter. Our working hypothesis was that the inactivation of CmeABC efflux pump 
would reduce, if not abolish, the emergence of FQ resistant Campylobacter. 
Point mutations in the 23 S rRNA gene were usually described responsible for 
erythromycin (a macrolide antibiotic) resistance in Campylobacter. Besides, CmeABC efflux 
pump was also recently shown to be involved in erythromycin resistance among 
Campylobacter isolates. However, further studies need to be performed to confirm and reveal 
the mechanisms of erythromycin resistance in Campylobacter. Also, although the resistance 
rate is still low at present, possible means to prevent the emergence of erythromycin 
resistance in Campylobacter need to be urgently explored as the frequency of macrolide-
resistant Campylobacter is on rise. 
In chapter 3, we describe that the expression level of the multi-drug efflux pump 
CmeABC influences the emergence of the ciprofloxacin (an FQ antibiotic)-resistant 
Campylobacter. Our results showed that over-expression of CmeABC increased the 
resistance frequency in Campylobacter against FQ and that knocking-out this pump greatly 
reduced the frequency of resistance development in this organism. 
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In chapter 4, we determine i) the in vitro occurrence of erythromycin resistance 
frequency in Campylobacter spp. under the antibiotic selection pressure; ii) the mechanisms 
responsible for erythromycin resistance; iii) and the effect of tylosin ( a macrolide antibiotic) 
treatment on the selection of erythromycin resistance in Campylobacter in experimentally 
infected chickens. Our in vitro results showed that there was no obvious difference between 
C jejuni and C. coli in terms of emergence of erythromycin-resistance frequency under the 
antibiotic selection pressure. 23S rRNA gene mutations were not detected in the in-vitro 
selected erythromycin resistant Campylobacter isolates. CmeABC pump was found be a 
contributing factor for both acquired and intrinsic erythromycin resistance in Campylobacter. 
Single or multiple tylosin treatments of chickens experimentally infected with different 
Campylobacter species/isolates, despite not killing all susceptible Campylobacter organisms 
in the gut, did not select for erythromycin resistant C. jejuni or C. coli. These findings 
suggest that therapeutic treatment of chickens with tylosin does not select for erythromycin-
resistant Campylobacter, which may explain, at least potentially, why erythromycin-resistant 
Campylobacter is less prevalent than FQ-resistant Campylobacter. 
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CHAPTER 2. LITERATURE REVIEW 
Campylobacter taxonomy and biology 
Campylobacter spp. were first observed and described as non-culturable spiral-shaped 
or Vibrio-like bacteria in 1886 by Theodor Escherich (39) and first isolated from an aborted 
bovine fetus in 1913 by McFadyean and Stockman (48). During that time they were 
classified in the genus Vibrio. After that, similar organisms were isolated from women who 
had abortion and infertile cows, ewes and sheep (21). In 1963, based on their low DNA base 
composition, microaerophilic growth requirements, and nonfermentative metabolism, Sebald 
and Veron created the new genus Campylobacter, which included two species: C. fetus and C. 
bubulus. Since then, many more species have been added to the genus due to the 
development of selective isolation methods for Campylobacter and continuous revision of 
the taxonomy with some misclassifications. According to the phylogenetic (16S rRNA 
similarity), genotypic and phenotypic analyses, currently the family of Campylobacteraceae 
is proposed to contain 4 genera: Campylobacter, Arcobacter, Sulfurospirillum and 
Bacteroides ureolyticu (21, 54). Within the genus Campylobacter, there are 14 species (C. 
jejuni, C coli, C lari, C upsaliensis, C helveticus, C fetus, C hyointestinalis, C mucosalis, 
C concisus, C curvus, C showae, C rectus, C sputorum, and C. gracilis), which show great 
phenotypic and genotypic heterogeneity. 
Campylobacter organisms are small curved or spiral shaped gram negative rods that 
exhibit rapid darting and spinning motions by use of polar flagella (21 ). Some species are 
nonmotile while there are some having multiple flagella. The members of the genus 
Campylobacter are microaerophilic, growing best in an atmosphere containing 5% 0 2, 10% 
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CO2 and 85% N2 . The optimum growth temperature for Campylobacter lies between 37-42 
~C. They are relatively slowly-growing and fastidious in nature, and since they can not 
ferment carbohydrates, energy is derived from the degradation of amino acids or 
tricarboxylic acid cycle intermediates. All strains except C. gracilis have oxidase activity, but, 
none have lipase or lecithinase activity. C. jejuni has a unique enzyme, hippurate hydrolase, 
which is critical to differentiate C. jejuni from other Campylobacter species. Because C. 
jejuni and C. coli are the two most important pathogens for human gastroenteritis, this review 
mainly focuses on these two species. Both C. jejuni and C. coli have a circular genome of 
approximately 1600-1700 kilo bases. The genomes have an average G+C content ranging 
from 29-47 mol¾. Campylobacter is capable of natural transformation, which enables them 
to take up foreign DNA and incorporate into their own genome, whereby the bacterium may 
acquire new characteristics. This fact has long been widely utilized by researchers to 
introduce DNA into Campylobacter . Contact-dependent plasmid DNA transfer, conjugation, 
is another method to introduce DNA into Campylobacter (77, 81). 
Campylobacterosis in humans 
a) Pathogenesis and disease symptoms 
Most cases of Campylobacter enteritis in humans are caused by C. jejuni and C. coli, 
and no difference is seen in the characteristics of disease due to either species. The symptoms 
of campylobacterosis often start as a cramping pain in the abdomen, and some individuals 
may develop fever, headache, dizziness and myalgia. Patients in developed countries usually 
have more severe symptoms than those in developing countries, with frequent development 
of bloody stool, fever and abdominal pain (20, 58). Bloody diarrhea sometimes can reach 10 
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or more times a day. Although the diarrhea will ease after 3 or 4 days, Campylobacter could 
be found in patients' feces even after several weeks if no antibiotic treatment is given. The 
duration of the illness varies from 4 to 14 days depending on the virulence of the infecting 
strain and the immune status of the patient (67, 76) . Rarely, Guillain-Barre syndrome (GBS), 
a serious post-infectious autoimmune-mediated neuropathy, is also shown triggered by C. 
jejuni infection (35) . In some particular C. jejuni strains, outer membrane polysaccharide 
structures and flagella can be sialylated, which mimic the gangliosides, resulting in the 
formation of autoantibodies leading to GBS ( 40). Besides surface polysaccharide structures, 
there are some other virulence factors in Campylobacter. To colonize in the host, motility, 
chemotaxis, adhesion and invasion abilities are required. Also to survive in low-iron, 
changed temperature, and oxygen-rich environments, iron acquisition, heat shock response 
and oxidative stress defense, respectively, are essential for Campylobacter (76). C. jejuni 
can produce a well-characterized toxin, cytolethal distending toxin (CDT), which induces 
secretion of the proinflammatory cytokine interleukin-8 from intestinal epithelial cells and is 
responsible for apoptosis of immune cells (31 , 83) . 
b) Immunity 
Epidemiological and volunteer studies have indicated that host immunity plays a 
major role in the pathogenesis of Campylobacter infections. Protective immunity develops 
after prior Campylobacter infection, which could protect against disease manifestations but 
not necessarily against colonization (80, 82). There is a correlation between levels of specific 
intestinal and systemic antibody and increased age in developing countries, which may 
explain the age-related decrease in the symptomatic Campylobacter infections in these 
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populations. Similarly, development of resistance to Campylobacter enteritis may frequently 
occur in populations that are occupationally exposed (slaughterhouse workers, veterinarians, 
and farmers) to this organism. Multiple exposures to Campylobacter could induce a broad-
range protective immunity, but the number of infections required to induce such cross-
protective immunity is unknown. 
c) Epidemiology 
Campylobacter is one of the most frequent causative bacteria isolated from patients 
with diarrhea in developed and developing countries. An incidence of 4 7 .6 cases per 100,000 
of the population (183,961 human cases) was reported by the European Food Safety 
Authority (EFSA) in 2006 (1). The data was collected from 21 European Union (EU) 
member states in 2004. The rate has increased by 32% compared with that in 2003. High 
incidence of Campylobacter-positive samples from animal products such as poultry, pigs and 
cattle was also reported, ranging from 64.2-91 % (1). In 2004, Foodborne Disease Active 
Surveillance Network (Foodnet) of CDC's Emerging Infectious Program reported an 
incidence of 12.9% for Campylobacter infections among the diseases caused by enteric 
food borne pathogens in 10 U.S. states, which is only second to salmonellosis (14. 7% 
incidence rate) for bacterial causes (2). In contrast to the EU countries, a 31 % of decrease in 
the incidence of infections with Campylobacter is shown from 1996-2004 in the 10 U.S . 
surveillance sites (2). The decline is a progress toward the national health objective of 12.3 
cases per 100,000 persons. Without national surveillance programs, there is no incidence data 
available for a population in developing counties. Instead, community-based studies 
estimated an incidence of 40,000 to 60,000/100,000 for children <5 years of age (14 ). The 
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incidence of disease in developing countries is several times more than that in developed 
countries. Because of high infection rates and increased exposure in developing countries, 
adults usually develop immunity to Campylobacter due to previous exposures. This fact 
makes campylobacterosis more a threat to children than to adults in developing countries. 
However, both children and adults in developed countries could have campylobacterosis 
once exposed to the pathogen. 
Campylobacter infections show distinct seasonality worldwide (22, 58). Transmission 
of Campylobacter is reported to relate to temperature, precipitation, humidity, sunlight hour 
and fly population in developed countries (41 , 43, 53). Thus, the peak of the Campylobacter 
infection could lie at spring, summer or fall , possibly depending on the combined effects of 
the risk factors. Reports on the seasonal differences of Campylobacter infections in the 
developing countries are limited, which might be explained by the poor national surveillance 
studies. However, some studies showed that there is less seasonal variation in developing 
countries. This observation suggests that the factors affecting the transmission of 
Campylobacter in developing countries have less seasonal variations (58). 
The majority of human Campylobacter illnesses come from consuming raw or 
undercooked poultry or other food products cross-contaminated with raw poultry meat during 
food preparation in the kitchen (15) . Poultry was demonstrated to be the major reservoir of 
Campylobacter in 1999 in Belgium. Numbers of human Campylobacter infections 
significantly fell down after a ban on the poultry meat, while the infection rate rose again 
once the ban was withdrawn (78) . C. jejuni and C. coli are also isolated commonly from 
other animal sources such as cattle, sheep, pigs and shellfish without causing any diseases in 
these animals (8 , 52, 84, 88), and thus consumption of products of these animals and contact 
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with them could be responsible for the infection. Human to human transmission of 
campylobacteriosis is rare except the cases of homosexual men (22). In a European survey 
from 1995 to 1999, food, unpasteurised milk and water were responsible for 48%, 15% and 
15%, respectively, of reported Campylobacter outbreaks. Surprisingly, 21 % of 
Campylobacter outbreaks had unknown or umeported causes (70). 
Clinical therapy 
Campylobacterosis is a self-limiting infection and thus no treatment is needed unless 
patients are (a) acutely ill and do not get better at the time a bacteriological diagnosis is made; 
(b) having a severe or systemic infection; ( c) immuno-compromised or suffering from 
predisposition to other bacterial infections (67) . FQs or erythromycin are the drugs of choice 
if treatment is required. However, FQs have lost their effectiveness because of the increasing 
resistance rate among Campylobacter spp. (3, 29, 33). Fortunately, the resistance rate to 
erythromycin is still low in most countries. When these two classes of drugs can't be used, 
tetracycline and chloramphenicol are the choices. However, the resistance rate to tetracycline 
has reached as high as 60%. Aminoglycosides are used in case of serious systemic infections 
(67). 
In addition to traditional antibiotic treatment, prevention is another way to control 
campylobacterosis. Observational and experimental studies provided evidence that acquired 
Campylobacter-immunity develops in humans exposed to Campylobacter (50, 80, 82), 
suggesting that prevention can be achieved by vaccination. Vaccines may be developed with 
killed or live attenuated Campylobacter. spp as immunogens. When administrated to high-
risk populations, these vaccines may help to prevent Campylobacter infections. Vaccines 
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against Campylobacter is currently under development (37, 79). Phase I safety and 
immunogenicity studies of a C. jejuni whole cell vaccine (CWC) have recently been 
completed (64). 
As mentioned in the epidemiology section, poultry meat is one major reservoir of 
Campylobacter. Elimination of Campylobacter.spp from poultry meat may be another way to 
prevent human infections. Experimentally, phages have already been shown to control 
Campylobacter growth, but the feasibility of supplementing phage in poultry meat to prevent 
infection needs further work (26). 
Campylobacter in poultry 
a) Prevalence and colonization 
Campylobacter is usually first detected in broiler chickens after 2-3 weeks of age in 
commercial farms, but newly hatched chickens can be experimentally infected with 
Campylobacter (61, 66, 86). The bacterium colonizes primarily in the lower intestines, and it 
is mainly found in the cecal and cloacal crypts. Up to 108 CFU (Colony Forming Unit) /g 
feces can be detected in the chick's intestinal tract without any clinical consequences. Thus, 
Campylobacter may be considered as a part of commensal flora in chicken host, and up to 
100% of broilers can carry this organism at slaughter age (3 6). 
b) Modes of transmission 
Both vertical and horizontal transmission have been suggested to be involved in the 
original introduction of Campylobacter into broiler flocks ( 61 ). Potential environmental 
sources could be old litter, untreated drinking water, other farm animals, domestic pets, 
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wildlife species, houseflies, insects, equipment and transport vehicles, and farm workers. 
However, no convincing evidence has been provided so far to prove any of these suspected 
sources as the formal source of infection for broiler farms. This is mainly because phenotypic 
or genotypic typing methods were not performed in many cases to compare the isolates from 
broilers and the environment, questioning the link between these putative sources and the 
flock infection (17, 27, 38, 60, 68). In those studies where the isolates from different sources 
were typed, it was hard to determine which one (broilers or environments) was the origin of 
the infection since no study plans for monitoring the direction of Campylobacter infection 
were included. Therefore, it was suspected that broilers, instead of being infected from the 
environment, might be the source of environmental contamination (11, 3 8, 69). Vertical 
transmission of Campylobacter in poultry production is considered unlikely to happen since 
young broilers less than 2 or 3 weeks of age usually are Campylobacter free and the 
bacterium is rarely, if at all, associated with eggs under natural conditions (7, 11, 65). 
c) Methods of detection for Campylobacter species 
Rapid and reliable detection is essential for tracking Campylobacter outbreak sources. 
Direct detection from fecal samples, which has a high level of background flora, could be 
tedious and time consuming. Both enrichment broths and selective agars are used to recover 
Campylobacter from field samples (34, 49). The selective media contain antibiotics to which 
Campylobacter are intrinsically resistant, such as polymyxin, vancomycin, trimethoprin, 
rifampicin, cefoperazone, cephalothin, colistin, cycloheximide and nystatin (16). They also 
contain oxygen-quenching agents such as blood, charcoal and hematin because 
Campylobacter are sensitive to oxygen levels over 5% (16, 73). The frequently used media 
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are Preston enrichment broth, Campythio, Campylobacter enrichment broth, Skirrow, 
Preston, Karmali, modified charcoal cefoperazone deoxycholate agar (mCCDA), 
cefoperazone amphotericin teicoplanin (CAT) agar, Campy-CV A ( cefoperazone vancomycin 
amphotericin), and Campy-Cefex medium (34). 
Immunology-based methods to detect Campylobacter such as enzyme immunoassays 
(EIA) are commercially available (34, 49). Although these methods are more rapid and easier 
to handle, the sensitivity is lower than the direct plating. PCR-based methods are also 
commonly used to detect Campylobacter in food, feces and environmental samples (34, 49). 
PCR has the advantage of sensitivity, specificity and rapidness. However, PCR only works 
best with pure cultures, and thus extraction of DNA from field samples is a pre-requisite 
before performing the PCR. Also, despite various purification methods, PCR might not work 
due to incomplete removal of PCR inhibitors in the sample. 
Antibiotic resistance in Campylobacter 
With the widespread use of fluoroquinolone and macrolide antibiotics in both animals 
and humans, resistance to these drugs has become a major public concern. Drug-resistant 
Campylobacter spp in humans may directly develop as a result of antibiotic treatment of 
patients, or indirectly accumulate from transmission of resistant isolates in animal 
populations via food chain ( 6, 10). 
Development of FQ-resistant Campylobacter following FQ treatment of animals has 
been demonstrated in both laboratory experiments and natural commercial settings (28, 45). 
In vitro, fluoroquinolone resistant C. jejuni could also be selected in fluoroquinolone 
supplemented agar plates with a frequency of 1o-8-10-9 (25, 57). In vivo , ciprofloxacin-
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resistant C. jejuni could rapidly evolve in chickens infected with a sensitive strain upon 
treatment with enrofloxacin (45, 47). The resistant strain could outcompete the sensitive 
strain and dominate in chickens even without antibiotic selection pressure ( 44 ). In humans, 
quinolone-resistant C. jejuni and C. coli were reported to develop in 3 out of 8 patients 
infected with quinolone-sensitive strains after norfloxacin or ciprofloxacin treatment ( 4, 85). 
In vivo development of resistance to macrolides was also observed in a patient infected by 
sensitive C. Jejuni after macrolide treatment (23) . 
Surveillance studies worldwide showed that the frequency of 
fluoroquinolone/macrolide resistance in Campylobacter differed from case to case and from 
location to location. High fluoroquinolone resistance in human and food animals is observed 
in Spain (80% in humans, 98.7% in animals), Netherlands (28% in humans, 29.3-34.7% in 
animals), UK (23% in humans), Egypt (24-40% in humans) and Thailand (73-77% in 
humans) . Relatively high macrolide resistance rate was reported in humans from Nigeria 
(16.7%), Ireland (13%) and Egypt (9-10%). In general, resistance to fluoroquinolones among 
Campylobacter is much higher than that to macrolides (56, 59). In the U.S., 10% of retailed 
chicken meat had ciprofloxacin-resistant Campylobacter (29). There is an increasing trend of 
fluoroquinolone resistance in human isolates from the US (0% in 1990, 13% in 1997, 20% in 
2002 ) (29) . A similar trend was observed in a U.K. survey (19), but an opposite trend was 
reported in raw poultry meat in Denmark, which was related to reduced use of 
fluoroquinolones in animals (5). Erythromycin resistance in humans has been kept steady at a 
level of approximately 1-2% in the U.S. from 1990-2002 (5). 
The mechanism of fluoroquinolone resistance in Campylobacter is mainly due to 
gyrA mutations with the help of the CmeABC efflux pump (87). The target of 
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fluoroquinolones may be the breakage-reunion domain of gyrase in the gyrase-DNA complex, 
explaining the mutations in gyraseA gene causing drug-resistance (51). MfpA, a pentapeptide 
repeat family protein in M tuberculosis could cause low-level ciprofloxacin resistance ( 4-8 
fold increase of MIC). This peptide has a ~-DNA like structure and can bind to gyrase, thus 
protecting it from fuoroquinolones (30). Blastp shows that a conceptacle pentapeptide repeat 
family protein (gene bank, gil57166352, ACC#: AAW35131) also exists in the complete 
genome of C. jejuni. It would be interesting to reveal whether this protein is expressed in 
Campylobacter and it contributes to fluoroquinolone resistance. 
23S rRNA mutations and efflux pumps were shown to contribute to macrolide-
resistance in Campylobacter (12, 24, 46). Macrolides bind exclusively to 23S rRNA of the 
SOS ribosomal subunit at the entrance of the tunnel of peptidyl transferase cavity, thus 
aborting the nascent protein synthesis (63). 23S rRNA mutations could significantly decrease 
its affinity to macrolides, explaining drug-resistance due to 23S rRNA mutations (75). 
Ribosomal protein L22 and L4 mutations could affect the conformation of 23S rRNA, and/or 
enlarge exit tunnel of peptide transferase cavity, leading to drug resistance (18, 75). However 
no L22 or L4 mutations have been reported in macrolide-resistant Campylobacter yet (24). 
In addition to target mutations and efflux pumps, horizontal gene transfer might be 
another mechanism for drug resistance. Plasmid mediated resistance to kanamycin, 
tetracycline, and cloramphenicol is found in Campylobacter (72) . These antibiotic resistance 
determinants were suggested to be acquired from the family Enterobacteriaceae, gram-
positive cocci or Clostridium. spp (9, 42, 55, 72, 74). Mechanisms responsible for gene 
transfer in Campylobacter include conjugation, natural transformation and bacteriophage 
transduction (71 ). 
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CHAPTER 3. ROLE OF THE CMEABC EFFLUX PUMP IN THE EMERGENCE OF 
FLUOROQUINOLONE-RESISTANT CAMPYLOBACTER UNDER SELECTION 
PRESSURE 
A paper to be submitted to Journal of Antimicrobial Chemotherapy 
Meiguan Yan, Orhan Sahin, Jun Lin and Qijing Zhang 
Abstract 
Fluoroquinolone (FQ) resistance m Campylobacter jejuni is mediated by gyrA 
mutations and the function of the CmeABC efflux pump. In this study, we examined the 
contribution of CmeABC to the emergence of FQ-resistant mutants under various levels of 
selection pressure (5x, 1 Ox, and 32x the MIC (Minimum Inhibitory Concentration) of the 
wild-type strain). Deletion of CmeABC had no effect on the emerging frequency of FQ-
resistant mutants at 5x the MIC, but drastically reduced the frequency of mutant emergence 
at lOx and 32x the MIC. In contrast, overexpression of CmeABC resulted in a 10-fold 
increase in the frequency of emergence of FQ-resistant mutants at 32x the MIC. Multiple 
types of gyr A mutations were detected in the FQ-resistant mutants selected at 5x and 1 Ox the 
MIC, while the Thr-86-Ile mutation was predominant in the mutants selected at 32x the MIC. 
While the Thr-86-Ile mutation was associated with high-level resistance to FQs, other 
changes only conferred intermediate-level FQ resistance. However, all types of gyrA 
mutations m the CmeABC-overexpressed background were associated with high-level 
resistance to FQs. Ciprofloxacin accumulation assay further indicated that CmeABC 
overexpression significantly reduced the amount of antibiotics accumulated within bacterial 
cells. These results indicate that CmeABC is not only important for maintaining high-level 
resistance to FQs, but is also required for the mergence of FQ-resistant mutants under high 
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selection pressure. Inhibition of this efflux pump may prevent the emergence of clinically 
relevant FQ-resistant Campylobacter mutants in clinical settings. 
Introduction 
Campylobacter jejuni is a major enteric pathogen causing gastroenteritis in humans 
worldwide (16, 18, 22, 30, 35, 38). Patients with campylobacteriosis often experience severe 
abdominal pain, fever, and watery/bloody diarrhea. In addition, Campylobacter infections are 
also occasionally associated with Guillain-Barre syndrome (OBS), an autoimmune disorder 
of the peripheral nervous system characterized by muscle weakness (20, 29). 
Fluoroquinolone (FQ) antimicrobials are often prescribed for clinical treatment of diarrhea 
caused by enteric bacterial pathogens including Campylobacter (31 ). However, the 
effectiveness of treatment has been compromised due to the increasing prevalence of FQ-
resistant Campylobacter commonly found in many countries, with some studies reporting a 
resistance rate up to 99% (2, 6, 16, 18). In developed countries, most of Campylobacter 
infections are foodborne, primarily from contaminated food , water, or raw milk, while 
person-to-person transmission rarely happens ( 40). 
Campylobacter spp. are highly prevalent in food producing animals, especially in 
poultry. Thus, many FQs-resistant Campylobacter stains in human patients are believed to be 
transferred from food producing animals, mostly from poultry ( 4 ). The FQs used in the food-
producing animals is considered a significant selective force for the development of FQ 
resistance in Campylobacter (14). Acquisition of FQ resistance also influences the fitness of 
Campylobacter in vivo , as is reported recently by Luo et al. that FQ-resistant Campylobacter 
outcompetes the FQ-susceptible Campylobacter in the intestinal tract of chickens (27). In 
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addition, FQ resistance can also increase the duration of the clinical illness caused by C. 
jejuni ( 10). Another recent report showed that patients infected with FQ-resistant 
Campy lobacter strains had more than 6-fold increase in the risk of having an adverse event 
compared with patients infected with FQ susceptible Campylobacter stains (15). Therefore, 
FQ-resistant Campylobacter is a significant threat to public health, and an augmented effort 
is needed to mitigate the emergence of FQ-resistant Campylobacter strains. 
The main targets of fluoroquinolones are DNA gyrase and/or topoiosomerase IV (9, 
17). In Campylobacter, spontaneous point mutations in the A subunit of gyrase (gyrA) are 
mainly responsible for the resistance. The locations of the point mutations are clustered in 
the QRDR (Quinolone Resistance-Determining Region) of gyrA , and different gyrA 
mutations confer varied levels of resistance to FQ antimicrobials (8) . Among different types 
of gyrA mutations found in Campylobacter, Thr86-Ile is the most frequently identified and 
can confer high-level resistance to fluoroquinolones (MIC2:16 µg/ml), while Asp90-Asn and 
Thr86-Lys can only achieve intermediate level-resistance ( 4µg/ml<MIC<l 6µg/ml) (28). 
Another mechanism found to be associated with FQ resistance in Campylobacter is the active 
efflux mediated by the multi-drug efflux pump CmeABC (7). CmeABC functions as an 
energy-dependent efflux system and contributes to the intrinsic and acquired resistance in 
Campylobacter to a broad-spectrum of antibiotics (25, 26, 34). CmeABC expression is 
regulated by a transcriptional repressor, named CmeR (23). CmeR binds to the inverted 
repeat in the promoter region of cmeABC and represses the transcription of the efflux operon. 
Insertional mutagenesis of the cmeR gene or mutation in the inverted repeat sequences 
resulted in over-expression of CmeABC, which elevates the resistance to multiple antibiotics. 
CmeABC and gyrA mutations work together to confer high-level FQ resistance in 
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Campylobacter because inactivation of CmeABC resulted in a significant reduction in the 
resistance level of clinical isolates harboring the resistance-associated mutations in gyrA (28). 
Spontaneous Campylobacter mutants resistant to FQ antimicrobials occur at a 
frequency of approximately 5 x 1 o-8 when selected in culture media using 4 µg/ml 
ciprofloxacin (12). In addition, Campylobacter displays a highly mutable phenotype in vivo 
in response to FQ treatment because a large number of FQ-resistant Campylobacter were 
detected in chickens or human patients treated with FQ antimicrobials (11, 13 , 37, 39). 
Although the genetic mechanisms for FQ resistance have been well understood, it is unclear 
what contributes to the emerging frequency of FQ-resistant Campylobacter. In Streptococcus 
pneumoniae and Pseudomonas aeruginosa, it has been shown that efflux pumps play an 
important role in the emergence of FQ resistance (19, 21 ). Since CmeABC contributes 
significantly to the intrinsic and acquired resistance to FQs in Campylobacter, we 
hypothesize that disruption of the CmeABC efflux system in Campylobacter will 
dramatically reduce, if not abolish, the frequency of the emergence of the FQ resistance. To 
test this hypothesis, we measured the mutation frequencies of FQ resistance in 
Campylobacter in various genetic backgrounds and determined the impact of various gyrA 
mutations and the expression levels of CmeABC on FQ resistance. 
Materials and methods 
Bacterial strains and culture conditions 
C. jejuni NCTC 11168 (32) and its isogenic cmeB mutant (l 1168B) and cmeR 
mutant (11168R) (3) were used in this study. Despite the repression by CmeR, CmeABC is 
constitutively expressed in 11168 and other wild-type strains at a moderate level (3 , 24). In 
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11168B, the cmeB gene was inactivated by a kanamycin resistance cassette ( cmeB:: kan) and 
the function of CmeABC was abolished, resulting in hypersensitivities to various antibiotics 
(3 ). In 1 l 168R, the cmeR gene was inserted with a chloromphenicol resistance cassette, 
disrupting the function of CmeR and leading to overexpression of CmeABC (23). These 
strains were routinely grown in Mueller-Hinton (MH) broth (Difeo) or agar at 42°C under 
microaerophilic conditions, which were generated using Campypak Plus (Becton Dickinson) 
gas pack in an enclosed jar. 
Detection of the emerging frequencies of ciprofloxacin-resistant mutants 
11168, 11168B and 11 l 68R were grown in 10 ml of antibiotic-free MH broth for 24 
hrs under microaerobic conditions. The cultures were collected by centrifugation and re-
suspended in 1 ml of MH broth. The total CFU s in the concentrated cultures were measured 
by serial dilutions and plating on MH plates. To estimate the emerging frequencies of FQ-
resistant mutants, each concentrated sample was plated onto duplicate antibiotic-free MH 
agar plates and ciprofloxacin-containing MH plates. This experiment was repeated three 
times. The concentrations of ciprofloxacin used for selction were: 0.625 µg/ml, which is 5-
fold minimum inhibitory concentration (MIC) in 11168; 1.25 µg/ml, which is 10 x the MIC; 
and 4 µg/ml, which is 32x the MIC and the suggested breakpoint for ciprofloxacin resistance 
in Campylobacter (12). The emerging frequency of FQ resistance was calculated as the ratio 
of the CFU on ciprofloxacin-containing MH agar plates and the CFUs on ciprofloxacin-free 
MH agar plates after 2-day's incubation at 42 °C. 
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Sequence analysis of the QRDR of gyrA 
Multiple resistant colonies were randomly selected from the ciprofloxacin-containing 
plates. The QRDR of gyrA gene was amplified by PCR using primer pair gyrA Fl (5'-
CAACTGGTTCTAGCCTTTTG-3') and gyrA Rl (5'-AATTTCACTCATAGCCTCACG-3') 
( 42). PCR was carried out for 35 cycles, each consisting of a denaturation ( 45 s at 95 °C), 
annealing (30 s at 52 °C), and extension step (1 min at 72 °C). The amplified PCR products 
were purified with the QIAquick PCR purification kit (Qiagen) prior to sequencing. DNA 
sequencing was carried out using an automated ABI Prism 3 77 sequencer and analyzed by 
Omiga 2.0 sequencing analysis software. Sequencing results were compared to the gyrA 
sequence of 11168 deposited in GeneBank with accession number NP_ 282177. 
Antimicrobial susceptibility test 
MICs of all the strains including the ciprofloxacin-resistant mutants were determined 
with the agar dilution method recommended by the NCCLS (1 ). Ciprofloxacin (Pentex 
Products), erythromycin, doxycycline, gentamicin (Sigma Chemical), and meropenem 
(AstraZenaca) were used in the susceptibility testing. 
Accumulation assay for ciprofloxacin 
The accumulation of ciprofloxacin in C. jejuni cells was determined as previously 
described with some modifications (25). Strains were grown in MH broth to the late log 
phase (24 hrs). The cells were harvested, washed once in 15 mM PBS (PH7.2), resuspended 
in PBS (PH7.2) to 1010- 11 CFU/ml (approximatelyl0 mg wet bacteria pellet), and incubated at 
37 °C for 10 minutes. Then Ciprofloxacin was added to the culture to a final concentration of 
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1 0µg/ml. After the addition of ciprofloxacin, 0.5 ml of each sample were removed at two 
different time points (3mins and 10mins), immediately diluted in 2.5 ml of ice-cold PBS, and 
then centrifuged for 5 min at 6,000 x g at 4 °C. The pellets were washed once with 2 ml of 
ice-cold PBS, resuspended in 2 ml of 0.1 M glycine hydrochloride (PH3 .0), and shaken at 
room temperature for 16 hrs. The samples were then centrifuged at 6,000 x g for 15 min . The 
fluorescence of the supernatant was measured with a Perkin-Elmer (Norwalk, Conn.) 
spectrofluorometer at excitation and emission wavelengths of 279 and 452 nm, respectively. 
The results were expressed as nanograms of ciprofloxacin per milligram (wet weight) of 
bacteria. Three independent experiments were performed to measure the accumulation of 
ciprofloxacin. 
Results 
Mutation frequencies in different genetic backgrounds 
To determine the influence of CmeABC on the emergence of FQ-resistant 
Campylobacter, three strains with different expression levels of cmeABC were used in this 
study, including 11168 (wild-type with a moderate level of CmeABC), 11168B (Cmeff), and 
11168R (CmeABC ovexpressed) (3 , 23). The results are summarized in Table 1. When 0.625 
µg/ml of ciprofloxacin was used for selection, all three strains showed similar levels of 
mutation frequency (:::::: 10-6, p~ 0.05). At 1.25µg/ml of ciprofloxacin, 11168 and 11168R 
showed similar mutation frequencies (:::::: 1 o-6) , while the mutation frequency in 11168B 
decreased dramatically to :::::: 10-9 _ The effect of the efflux pump on the emergence of FQ-
resistant mutants was even more prominent at the higher selection pressure ( 4µg/ml 
ciprofloxacin), at which the frequency of emergence of ciprofloxacin-resistant mutants was 
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about 10-fold higher (p < 0.05) in 11168R (;:::; 10-7) than in 11168 (;:::;10-8), while the mutation 
rate in 11168 was more than 100-fold greater (p<0.05) than in l 1168B (< 10-10) . These 
results clearly indicated that inactivation of CmeABC decreased the emerging frequencies of 
FQ-resistant mutants under selection pressure, especially at the higher antibiotic 
concentrations, while over-expression of CmeABC resulted in the increase of the emerging 
frequency of FQ-resistant mutants. 
Different point mutations in gyrA were detected in the FQ-resistant mutants 
Mutations in gyrA were found to be present in all the ciprofloxacin-resistant mutants 
examined in this study, and each of the mutants carried a single point mutation in the QRDR 
(Table 2). Four different types of point mutations were observed, including Thr-86-Ile, Thr-
86-Lys, Asp-90-Asn, and Asp-90-Tyr. The first three types of mutations have been reported 
previously (8), while the Asp-90-Tyr change represents a new mutation identified in FQ-
resistant Campylobacter mutants. For the mutants selected on plates containing 0.625 µg/ml 
and 1.25 µg/ml ciprofloxacin, all four types of mutations were detected; however, the Thr-
86-Ile change was the only mutation detected in 11168 mutants selected on plates containing 
4 µg/ml ciprofloxacin, indicating that only the mutants carrying the Thr-86-Ile mutation can 
survive the high selection pressure. This finding is consistent with previous findings that the 
Thr-86-Ile mutation can confer a high-level resistance to FQs, while other mutations confer 
intermediate-level FQ resistance in Campylobacter (28). Notably, no mutants were detected 
in 11168B on plates containing 4 µg/ml of ciprofloxacin, indicating that CmeABC is 
essential for the survival of the gyrA mutants und~r high selection pressure. Another 
interesting finding was that the mutants of l l l 68R selected on 4 µg/ml ciprofloxacin had two 
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types of mutations including Thr-86-Ile and Thr-86-Lys, suggesting that the Thr-86-Lys was 
also able to confer high-level FQ resistance in the CmeABC-overexpressed background. 
Effect of different GyrA mutations and the expression level of CmeABC on cipro MICs 
The MIC of ciprofloxacin in the mutants selected from different genetic backgrounds 
and under different selection pressures was determined by the agar dilution method (Table 3). 
In the 11168 background, all mutants carrying the Thr-86-Ile mutation had a cipro MIC of 16 
µg/ml, while the mutants carrying other types of GyrA mutations had cipro MIC of 4 µg/ml, 
confirming that the Thr-86-Ile change confers a high-level-resistance to ciprofloxacin. All of 
the mutants selected from l 1168B had ciprofloxacin MI Cs .'.S 4 µg/ml regardless of the types 
of GyrA mutations, which suggests that without a functional CmeABC none of the GyrA 
mutation can confer a high-level FQ-resistance and explains why no mutants were selected 
from l 1168B at 4 µg/ml of ciprofloxacin. In contrast, all of the mutants selected from 
11168R had a ciprofloxacin MIC of 16 µg/ml regardless of the types of GyrA mutations, 
indicating that in the CmeABC-overexpressed background all types of GyrA mutations can 
confer a high-level resistance to ciprofloxacin. These findings clearly indicate that FQ 
resistance in C. jejuni mutants is affected not only by the point mutations in GyrA, but also 
by the expression level of CmeABC. We also tested the MICs of several other antibiotics in 
the FQ-resistant mutants, none of which showed cross-resistance to other antibiotics 
including erythromycin, doxycycline, gentamicin and meropropeline (Data not shown). 
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Decreased accumulation of ciprofloxacin in 11168R 
Previously work performed by us and others has shown that the cmeB mutants 
accumulated more ciprofloxacin than their wild type strains (25 , 34). Since all of the 11168R 
mutants showed high-level resistance to ciprofloxacin, we suspected that this was related to 
reduced accumulation of ciprofloxacin within the cells due to enhanced efflux by CmeABC. 
To test this possibility, we compared the accumulation of ciprofloxacin in 11168 and 11 l 68R. 
As shown in Fig. 1, three independent experiments showed that 11168R accumulated 
approximately 40% less ciprofloxacin than the wild-type 11168 did (P<0.05). This finding 
suggests that the increased efflux contributes to the high FQ resistance in the 11168R 
mutants. 
Discussion 
This study demonstrated that the expression level of cmeABC affects the emerging 
frequency of FQ-resistant mutants in Campylobacter. This conclusion was based on several 
observations. Firstly, the emergence frequency of FQ-resistant mutants in the CmeABC null 
mutant (11168B) was significantly lower than that of the wild-type strain at 1 Ox and 32x the 
MIC (Table 1). Secondly, 11168R, in which cmeR is overexpressed, had a significantly 
higher emergence frequency of FQ-resistant mutants than the wild-type strain (Table 1 ). 
Thirdly, the same type of gyrA mutation conferred different levels of resistance to 
ciprofloxacin in different genetic background with varying levels of CmeABC expression 
(Table 2). Finally, 11168R accumulated significantly less amount of ciprofloxacin than the 
wild-type strain (Figurel). Together, these findings indicate CmeABC promotes the 
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emergence and survival of FQ-resistant mutants by reducing the accumulation of FQ 
antimicrobial in Campylobacter cells. 
The frequency of the emergence of ciprofloxacin-resistant mutants was similar (::::1 o-6) 
at 5x the MIC, regardless of the expression status of cmeABC (Table 1 ), suggesting that all of 
the resistance-associated gyrA mutations, without the help of CmeABC, can confer a level of 
resistance to ciprofloxacin 2: 0.625 µg/ml. However, when 1 Ox the MIC (1.25 µg/ml ) was 
used for selection, the frequency of emergence of FQ-resistant mutants for 11168B dropped 
1000-fold to 10-9 , while the emergence frequency stayed at about the same level (:::: 10-6) for 
the wild-type strain and 11168R mutant. At 32x the MIC ( 4 µg/ml ciprofloxacin), which is 
the recommended breakpoint for Campylobacter resistance (12), the frequency dropped 100-
fold to 1 o-8 for the wild-type strain and 10-fold to 10-7 for 11168R overexpressing CmeABC; 
however, no resistant colonies were selected from the 11168B mutant strain, which lacked a 
functional CmeABC efflux pump. These results indicate that the emergence frequency of the 
FQ-resistant mutants decreased with the increase of selection pressure and that the expression 
level of CmeABC influences the occurrence of the ciprofloxacin-resistant mutants. Without a 
functional CmeABC, the frequency of emergence of ciprofloxacin-resistant mutants was less 
than 10-10 in plates containing 4 µg/ml ciprofloxacin. Since 4 µg/ml is considered a 
breakpoint for clinical resistance, inactivation of CmeABC may abolish the emergence of 
FQ-resistant mutants with clinical relevance. Thus, the CmeABC pump may be targeted to 
avoid the emergence of the ciprofloxacin-resistant Campylobacter . 
In this study we identified the Thr-86-Ile, Thr-86-Lys, and Asp-90-Asn gyrA 
mutations in the ciprofloxacin-resistant mutants as reported by Wang et al ( 42) and by Ruiz 
et al (36). Another type of mutation, Asp-90-Tyr, has been described in C. coli with high-
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level cipro:floxacin resistance and C fetus with low-level cipro:floxacin resistance ( 41 ), but 
has not been reported previously in C. jejuni strains. We found that Asp-90-Tyr is associated 
with low level resistance to cipro:floxacin (4µg/ml) in 11168 (Table 3). We did not observe 
the Ala-70-Thr mutation, additional amino acid changes, or silent mutations in the QRDR of 
GyrA as reported by other researchers (5, 42). This could be due to the infrequent nature of 
the Ala-70-Thr mutation, which was not present in the small number of mutants sequenced in 
this study. Another interesting observation of this study is that the Thr-86-Ile mutation was 
not predominant in the mutants selected on plates containing 0.625 and 1.25 µg/ml of 
cipro:floxacin, but was dominant in the mutants selected on plates containing 4 µg/ml of 
cipro:floxacin (Table 2). This finding suggests that different type of mutations in the QRDR 
of GyrA occur at similar frequencies , but the Thr-86-Ile change is the one that can be 
selected by high selection pressure. It may also explain why the Thr-86-Ile mutation is the 
most frequently observed change in FQ-resistant Campylobacter isolated from animal 
reservoirs and clinical settings. 
It has been known from previous reports that the Thr-86-Ile mutation m 
Campylobacter can confer a high-level resistance to FQs (~ 16 µg/ml), while the Asp-90-Asn 
or Thr-86-Lys mutations only results in an intermediate-level of resistance (28, 42). In this 
study, the 11168 mutants with the Thr-86-Ile mutation had a cipro MIC of 16 µg/ml, but for 
other types of mutations the MIC could only reach 4 µg/ml (Table 3). In contrast, all of the 
11168R mutants showed a cipro MIC of 16µg/ml, regardless of the types of GyrA mutations. 
This finding suggests that overexpression of CmeABC directly contributes to high-level FQ 
resistance in Campylobacter, which explains why mutants with the Thr-86-Lys mutation 
were selected from 11168R, but not from 11168 on plates containing 4 µg/ml of 
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ciprofloxacin (Table 2). The lack of mutants of l 1168B on plates containing 4 µg/ml 
ciprofloxacin (Table 2) indicates that without the function of CmeABC no Campylobacter 
mutants could survive the high selection pressure, further proving the importance of 
CmeABC in the acquired resistance to FQ antimicrobials. 
In our previous work, we showed that CmeABC played a major role in the efflux of 
ciprofloxacin in C. jejuni and inactivation of cmeB resulted in increased ciprofloxacin 
accumulation in the bacterial cells (25). Here, we compared ciprofloxacin accumulation in 
11168 and 11168R, which revealed that there were about 40% less ciprofloxacin 
accumulation in the 11168R strain than in the wild-type strain (Fig. 1 ). This observation 
further confirmed that CmeABC efflux pump contributes to the efflux of ciprofloxacin and 
that over-expression of CmeABC increases the resistance level to FQs in Campylobacter. 
To our knowledge, this is the first study that showed the direct effect of CmeABC 
expression on the emergence and resistance levels of FQ-resistant mutants of C. jejuni. These 
new results, along with our previous findings that CmeABC is an important player for 
multidrug resistance and in vivo colonization by mediating bile resistance (24, 25), provide a 
strong rationale for targeting CmeABC to reduce the occurrence and spread of antibiotic 
resistant Campylobacter. Since CmeABC is present in every strain of C. jejuni (25, 33 , 34), 
an inhibitor or blocker of CmeABC will have a role in anti-Campylobacter activity. 
Inhibition of CmeABC not only prevents the emergence of FQ-resistant mutants of clinical 
significance, but also promotes the clearance of Campylobacter from the intestinal tract of 
animal hosts. 
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Table 1. The emergence frequency of FQ-resistant C. jejuni mutants under 
different selection pressures* 
Ciprofloxacin Frequency (mean±SD) 8 
Levels (µg/ml) 
11168 11168B 11168R 
0.625 1.17± 1.06x 10-6 a 1.43±1.64x10-6 a 3.89±3.39x10-6 a 
1.25 1.27±0.91x10-6 a 3.66±2.54x10-9 b 3.92±3.69x10-6 a 
4 1.99±0.19x 10-Sa <9.7x10-!0b 3.42±3.48x10-?c 
* Mean± standard deviations of three independent experiments 
8 Means in the same row with different superscript letters differ significantly 
(p<0.05 , ANOV A) 
35 
Table 2. Types of GyrA mutations in representative ciprofloxacin-resistant mutants 
selected under different conditions* 
Background GyrA mutations in mutants selected on plates with different 
strain ciprofloxacin concentrations 
0.625 µg/ml 1.25 µg/ml 
11168 Asp90-Tyr (3) Asp90-Tyr (3) 
Asp90-Asn (2) Thr86-Ile (3) 
l 1168B Thr86-Lys (6) Asp90-Tyr (6) 
Asp90-Tyr (2) Thr86-Ile (3) 
11168R Asp90-Tyr (3) Asp90-Tyr ( 5) 
Thr86-Lys (3) Thr86-Lys (1) 
4 µg/ml 
Thr86-Ile (6) 
NMD 
Thr86-Lys (4) 
Thr86-Ile (2) 
* The number in parentheses indicates the number of the examined mutants with 
the same type of mutation. 
NMD: no mutant detected. 
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Table 3. Cipro MI Cs of the FQ-resistant mutants selected from different 
genetic background 
Parent Mutants selected MIC Mutants selected MIC Mutants selected MIC 
strain on 0.625µg/ml (µg/ml) on 1.25µg/ml (µg /ml) on 4 µg/ml 
ciprofloxacin ciprofloxacin ciprofloxacin 
11168 Asp90-Tyr 4 Asp90-Tyr 4 Thr86-Ile 16 
Asp90-Asn 4 Thr86-Ile 16 
11168B Thr86-Lys 4 Asp90-Tyr 2 NMD 
Asp90-Tyr 4 Thr86-Ile 4 
11168R Asp90-Tyr 16 Asp90-Tyr 16 Thr86-Lys 16 
Thr86-Lys 16 Thr86-Lys 16 Thr86-Ile 16 
NMD : no mutants detected 
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FIG 1. Level of ciprofloxacin accumulation in C. jejuni 11168R in relative to the level in 
11168. The data is presented as the ratio of the amounts of ciprofloxacin accumulated in 
l 1168R and 11168. Each data point represents the mean ± standard deviation of three 
independent experiments. 
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CHAPTER 4. EMERGENCE FREQUENCIES AND GENETIC MECHANISMS OF 
MACROLIDE RESISTANCE IN CAMPYLOBACTER JEJUNI AND 
CAMPYLOBACTER COLI 
A paper to be submitted in Antimicrobial Agents and Chemotherapy 
Meiguan Yan, Orhan Sahin, Sonia Pereira and Qijing Zhang 
Abstract 
Campylobacter has become increasingly resistant to erythromycin, a macrolide 
antibiotic and the most commonly used drug to treat human Campylobacter infections. 
Although macrolide usage in agriculture is considered a major driving force for the 
increasing resistance rate, its actual contribution to the emergence and prevalence of 
macrolide-resistant Campylobacter in food producing animals remain to be elucidated. In this 
study the effect of macrolide treatment on the emergence of erythromycin resistance in C. 
jejuni and C. coli and the genetic mechanisms associated with the resistance are investigated 
using both in vitro and in vivo studies. In vitro plating of C. jejuni or C. coli cultures on MH 
agar plates with erythromycin revealed that both Campylobacter species had similar, but low 
mutation rates (approximately 10-10) to erythromycin. Chickens infected with C. jejuni or C. 
coli were subject to single or multiple treatments with tylosin using the dose and regime 
recommended for poultry production. The treatments transiently reduced the level of 
Campylobacter colonization in chickens, but did not select or enrich erythromycin-resistant 
mutants in the treated chickens. This finding is in contrast to the rapid emergence of 
fluoroquinolone-resistant Campylobacter in chickens treated with enrofloxacin (29). 
Interestingly, the in vitro selected erythromycin-resistant mutants did not have the known 
resistance-associated mutations in the 23S RNA gene; however, inactivation of CmeABC, a 
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multidrug efflux pump, completely abolished the resistance to erythromycin, indicating that 
CmeABC is important for macrolide resistance. Together, these results reveal the complex 
nature of macrolide resistance in Campylobacter in animal reservoirs and suggest that 
therapeutic treatment with tylosin has a limited impact on the emergence of macrolide-
resistant Campylobacter in chickens. 
Introduction 
Thermophilic Campylobacter spp. (including C. jejuni and C. coli) have been 
recognized as one of the most commonly detected bacterial pathogens causing human 
gastrointestinal enteritis (18). As an enteric organism, Campylobacter resides in the 
gastrointestinal tract of domestic and wild animals ( 4, 13, 40, 44). The majority of human 
Campylobacter infections are associated with consumption of undercooked poultry and meat 
products as well as raw milk (20, 22, 40). 
Fluoroquinolones (FQs) and macrolides are the two key classes of drugs used for 
treating human campylobacteriosis. However, the increasing resistance of Campylobacter to 
these antimicrobials has been a major concern for public health. The prevalence of antibiotic-
resistant Campylobacter continues to increase both on farms and in the hospital settings (1, 
3). Due to the high resistance rate of Campylobacter to FQs, erythromycin, a macrolide 
antibiotic, has become the drug of choice for treatment (3). However, several reports indicate 
that erythromycin resistance in Campylobacter also is on the rise (26, 33, 37). The trend is 
especially alarming with C. coli because higher resistance rates to erythromycin have been 
reported for this Campylobacter species (6, 7, 24, 33 , 38). 
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Macrolides antibiotics inhibit bacterial growth by binding to procaryotic ribosomes 
and interfering with protein synthesis (12). Antibiotic modifications, target site alterations, 
and drug efflux are the three main mechanisms involved in macrolide resistance in bacteria 
(23). However, no studies have reported evidence of macrolide modification in 
Campylobacter. In both C. jejuni and C. coli, point mutations in the 23S rRNA gene have 
been associated with macrolide resistance (9, 14, 17, 19, 31 ). Specifically, the resistance-
associated mutations occur at the base position of 2074 (A2074C, A2074G or A2074T) 
and/or 2075 (A2075G or A2075C) in the 23S rRNA gene of Campylobacter, which 
correspond to the base positions 2058 and 2059, respectively, in E. coli (14, 17, 19, 31). 
There are three copies of the 23S rRNA gene in C. jejuni and C. coli (11 , 35). Usually all 
three copies of the 23S rRNA gene are mutated, and both the wild-type and mutated alleles 
can co-exist in a single macrolide-resistant mutant (14, 19, 31). The multidrug efflux pump 
CmeABC of C. jejuni contributes to the intrinsic resistance to macrolides (25). Another study 
showed that CmeABC is also involved in the acquired resistance to erythromycin (8). In 
addition, an unidentified efflux pump, which is sensitive to phenylalanine-arginine ~-
naphtylamide (P A~N), also contributes to the intrinsic and acquired resistance of 
Campylobacter to macrolides (30, 36). 
There is a general trend that C. jejuni and C. coli are increasingly resistant to 
macrolide antibiotics. Since macrolides are used extensively for growth promotion and 
therapeutic purposes in food producing animals including poultry, it has been a concern 
whether exposure of chickens to therapeutic or subtherapeutic doses of macrolides promotes 
the emergence of macrolide-resistant Campylobacter, as is reported with FQ antibiotics (5 , 
15, 28). A better understanding of the factors influencing the occurrence and spread of 
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macrolide resistance in Campylobacter will facilitate the design of strategies to promote the 
prudent use of antibiotics on farms and control the prevalence of antibiotic resistant 
Campylobacter. Toward this aim, we examined emergence frequencies of macrolide-resistant 
C. jejuni and C. coli in culture media and in chickens treated with tylosin and determined the 
molecular mechanisms associated with the observed resistance. 
Materials and methods 
Bacterial strains and culture conditions 
Two C. jejuni strains, including S3B (29) and W7, and 4 C. coli strains: RN14B and 
MR32D (from swine) and A W-II:35 and A W-II:37 (from poultry), were used in this study. 
W7 was a motile variant of ATCC 700819, which is the same strain as NCTC 11168 (35). 
All these strains are sensitive to erythromycin. All strains have an erythromycin MIC of 2 
µg/ml except AW-II:35 and AW-II:37 (MIC= 0.125 µg/ml). Strains were grown routinely on 
MH agar plates or in MH broth at 42°C under microaerophilic conditions. Campylobacter-
specific growth supplements and selective agents (Oxoid) were added to the media when 
needed. When indicated, the culture media was also supplemented with various amounts of 
erythromycin (Sigma chemical Co. , St. Louis, MO). 
Emergence frequencies of erythromycin-resistant C. jejuni and C. coli in vitro 
C. jejuni and C. coli cultures were grown in antibiotic-free MH broth to late 
logarithmic phase. The cultures were plated in duplicate on antibiotic-free MH agar plates 
and erythromycin-containing plates (2, 4 or 8 µg/ml). The plates were incubated for two days, 
and the colonies on each type of plates were used to calculate CFUs. The frequency of 
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macrolide resistance was calculated as the ratio of the numbers of CFU on erythromycin-
containing plates versus the CFU on erythromycin-free plates. The experiment was repeated 
three times. Although there is currently no NCCLS-approved standard for Campylobacter 
susceptibility testing, the MIC of 8 µg/ml is suggested as the breakpoint for erythromycin 
resistance (10) . 
Antibiotic susceptibility test 
Minimal inhibition concentration (MIC) of antibiotics were tested using the agar 
dilution method as recommended by the NCCLS (32). Erythromycin was purchased from 
Sigma chemical Co., St.Louis, MO. 
Sequence analysis of the 23S rDNA 
The 23S rRNA gene sequence of C. jejuni and C. coli (MIC2:8 µg/ml) was amplified 
by PCR with specific pnmers (5'-GTAAACGGCGGCCGTAACTA-3' and 5'-
GACCGAACTGTCTCACGACG-3') (19). PCR reaction conditions were as follows: 94°C, 5 
mins; 94°C, 30 s; 52°C, 30s; 72°C, 40s for 35 cycles and a final extension at 72°C, 10 mins. 
The amplified PCR products were purified with the QIAquick PCR purification kit (Qiagen) 
prior to sequencing. DNA sequencing was carried out using automated ABI Prism 377 
sequencers (Applied Biosystems Inc) and analyzed by Omiga 2.0 (Oxford Molecular Ltd). 
Immunoblotting analysis of CmeABC expression 
To examine if CmeABC was over-expressed in the erythromycin-resistant isolates, 
CmeA, CmeB and CmeC protein of erythromycin-resistant isolates S3BE2-2 and S3BE4-3 
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(erythromycin MIC = 256, 128µg/ml; no mutation in 23S rRNA) as well as their parent 
strains S3B were analyzed by immunoblotting with antibody specific for CmeA, CmeB and 
CmeC as described previously (25). 
Construction of cmeB mutants in erythromycin-resistant isolates 
Natural transformation was used to construct Campylobacter cmeB mutants in the 
erythromycin-resistant isolates. Genomic DNA of 11168B (cmeB: :kan) was used as the 
donor DNA in the transformation, while erythromycin-resistant isolates S3BE2-2, 
RN14BE4-3 , and RN14BE2-2 were used as the recipient strains. Natural transformation was 
performed on a biphasic method as described by Wang at al (42). Transformants were 
selected on plates containing 30 µg/ml of kanamycin. The insertion of the kanamycin 
cassette into the cmeB gene was confirmed by PCR. 
Tylosin treatment of Campylobacter-colonized chickens 
Day old broiler chickens were purchased from a commercial hatchery and randomly 
assigned into multiple groups (10-15 birds per group). Each group of chicks were housed 
separately in a sanitized wire-floored cage and provided with non-medicated food and water 
ad libitum. Each chicken was inoculated with a fresh culture of approximately 10 7 CFU of 
Campylobacter via oral gavage at the age of 3-days. C. jejuni S3B and W7 strains were used 
as inoculum in Experiment 1. Birds in the control groups were inoculated with either S3B or 
W7 alone and did not receive any tylosin treatment. Birds in the experimental groups were 
inoculated with the same strains, but were subjected to a single tylosin (Tylan\ Soluble; 
Elanco Animal Health) treatment starting on day after inoculation (DAI) 4 or 5. Each single 
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tylosin treatment lasted for three days and the drug was given to the chickens via drinking 
water using the dose approved for commercial poultry production (2g/gallon water) . Cloaca! 
swabs were collected from the chickens before and after tylosin treatment until the end of 
experiment on DAI 10-15. Each swabs were diluted serially in MH broth and each dilution 
were plated onto two different types of MH plates, one containing Campylobacter-specifi.c 
selective agents and growth supplements (Oxoid) to recover the total Campylobacter 
populations, and the other containing the selective agents and supplements plus 8 µg/ml 
erythromycin to recover the macrolide-resistant population in each sample. Campylobacter 
colonies were counted following 48h of incubation at 42°C under microaerobic atmosphere. 
In addition, representative colonies (IO/group) were collected from erythromycin-free plates 
at each sampling time for MIC testing using the standard agar dilution method (32). Isolates 
having an MIC of ~ 8 µg/ml were considered resistant to erythromycin, which is the same 
cut-off value used by the National Antimicrobial Resistance Monitoring System (10). 
Experiment 2 was done in the same way as Experiment 1 except that a mixture C. coli strains 
AW-II: 35 and AW-II: 37 were used to inoculate chickens. In Experiment 3, which was 
conducted in a similar way to Experiments 1 and 2, chickens in the experimental groups were 
subjected to multiple tylosin treatments (a total of 3 treatments) at weekly intervals. The 
duration of Experiment 3 was consequently longer (approximately 30 days). 
Results 
C. jejuni and C. coli have similar, but low frequencies of emergence of erythromycin-
resistant mutants in vitro 
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To determine the frequencies of emergence of erythromycin resistance in C. jejuni 
and C. coli under antibiotic selection pressure, two C. jejuni strains (S3B and W7) and two C. 
coli strains (RN14B and MR32D) were plated on MH agar plates containing 4 or 8 µg/ml 
erythromycin. The frequency of emergence of erythromycin resistance was low (3 x 10-9 to 
:S l 0- 10) (Table 1 ). There was no detectable differences for the emerging frequency of the 
resistance at 4 µg/ml and 8 µg /ml of erythromycin (ANOVA, P < 0.7135) for all of the 
strains tested (Table 1 ). In addition, there were no differences in the resistance emergence 
frequencies between C. coli and C. jejuni regardless of the concentrations of erythromycin 
used on the plates. Our findings indicate that the frequency of emergence of erythromycin-
resistant Campylobacter (approximately 10-10) was much lower than that with 
fluoroquinolones (approximately 5 x 1 o-8 with 4 µg/ml of ciprofloxacin). 
MI Cs and sequencing of the in vitro selected erythromycin-resistant mutants 
The MICs of representative erythromycin-resistant mutants were listed in Table 2. 
The majority of the mutants obtained from a single-step selection had an erythromycin MIC 
of 32 µg/ml. Interestingly, only one of the mutants (RN14BE4-2) had the previously 
reported mutation in the 23S RNA gene (A2074G substitution) . According to the sequence 
result, the A2074G mutation was only in one copy of the three 23SRNA genes in RN14BE4-
2, because there were double peaks in the same position on the sequence chromatogram. The 
lack of 23S rRNA mutations in other mutants suggested that other mechanisms were also 
involved in erythromycin resistance. 
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CmeABC contributed to macrolide resistance 
To determine the molecular basis of macrolide resistance in the selected mutants, the 
level of cmeABC expression was compared between the parent strains and their mutants. 
Immunoblotting results indicated that there were no significant differences in the expression 
levels of CmeA, CmeB and CmeC (Fig. 4), suggesting that cmeABC was not overexpressed 
in the erythromycin-resistant mutants. The cmeB gene in the erythromycin-resistant isolates 
was also inactivated by insertional mutagenesis to further determine the contribution of this 
efflux pump to the acquired erythromycin resistance in Campylobacter. As shown in Table 3, 
the erythromycin MI Cs of the cmeB mutants decreased drastically to a level even below the 
MICs of the parent strains (Table 3) . These findings indicated that CmeABC can directly 
contribute to the acquired erythromycin resistance in Campylobacter, even though the efflux 
pump was not overexpressed in the mutants. 
Effect of tylosin treatment on the emergence of erythromycin-resistant Campylobacter 
in chickens 
To determine the influence of tylosin treatment on the development of macrolide-
resistance in Campylobacter, broiler chickens were first infected with C. jejuni or C. coli and 
then were treated with tylosin (single or multiple times) via drinking water (2g/gal) for 3 
consecutive days. In the first experiment chickens inoculated with C. jejuni (S3B or W7) 
were quickly colonized and shed the organism at the level of 105-107cfu/g feces right before 
the initiation day of tylosin treatment (Figure. 1 ). Two days after the initiation of the tylosin 
treatment, the number of colonized chickens dropped drastically, with only a few chickens 
shedding detectable Campylobacter. However, the number of colonized chickens increased 
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steadily and reached the level of the non-treated groups 4 or 6 days after the initiation of 
antibiotic treatment (Fig. 3). The few chickens that remained colonized on day 2 after 
initiation of the tylosin treatment had low numbers of organisms in the feces (Fig. I). 
However, the colonization level also increased steadily as the percentage of colonized birds 
elevated, and it reached the level of non-treated group at 1 or 3 days after the cessation of 
treatment. Non-treated chickens remained colonized and shed Campylobacter at 
approximately I 06 CFU/g feces throughout the study (Fig. 1 ). During the entire experiment, 
no Campylobacter colonies were observed on plates containing 8 µg/ml erythromycin. This 
observation indicated that a single tylosin treatment of chickens did not select for 
erythromycin-resistant Campylobacter jejuni isolates despite the fact that C. jejuni survived 
the tylosin exposure. Representative colonies (IO isolates /sampling/ group) collected from 
the chickens were tested with the agar dilution method for MIC of erythromycin. All of the 
isolates had the same erythromycin MIC (2 µg/ml) as that of the parent strains S3B and W7, 
further confirming that the single tylosin treatment did not select for erythromycin-resistant 
Campylobacter. In the second experiment, the chickens were infected with a mixture of 2 
strains of C. coli and then treated with tylosin. As shown in Fig. 2, similar results to those of 
the C. j ejuni experiment were obtained following the treatment. No erythromycin-resistant 
mutants were detected in any of the treated chickens by either plating method (8µg/ml 
erythromycin) or MIC test. The findings from the C. coli experiment confirmed the results 
from the first experiment with C. j ejuni and indicated that a single tylosin treatment did not 
select for macrolide-resistant Campylobacter in chickens. Similarly, multiple tylosin 
treatments (total of 3 treatments) of chickens inoculated with C. jejuni W7 strain (Experiment 
3) did not promote the emergence of macrolide-resistant Campylobacter (Fig. 3). Together, 
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these results indicated that the exposure of chickens to therapeutic doses of macrolides did 
not result in the selection of erythromycin resistant Campylobacter organisms regardless of 
the number of treatments or the species of Campylobacter tested. 
Discussion 
In this study, the results from both in vitro and in vivo experiments indicate that C. 
jejuni and C. coli have a low mutation rate to macrolide antibiotics compared to the mutation 
rate to fluoroquinolones. Previous studies by us and other researchers (15 , 16, 28) showed 
that C. jejuni is highly mutable to fluoroquinolone treatment and fluoroquinolone-resistant 
mutants occurred in the treated chickens within 24 hours after the initiation of treatment. The 
FQ-resistant mutants eventually replaced the susceptible population and colonized the FQ-
treated chickens. This difference in Campylobacter response to the treatments with the two 
different classes of antibiotics is likely due to the dissimilarity in their modes of action and 
the molecular mechanisms associated the resistance. Macrolides target bacterial ribosomes 
and inhibit protein synthesis, while fluoroquinolones target DNA gyrase and inhibit DNA 
replication and transcription. It is possible that the gyrase gene in Campylobacter has a 
higher spontaneous mutation frequency than the 23 S rRNA gene, leading to the rapid 
emergence of FQ-resistant mutants under selection pressure. The low mutation rate of 
Campylobacter to macrolide antibiotics revealed in this study may explain the relatively low 
prevalence of macrolide-resistant Campylobacter in poultry. 
There is a general trend that macrolide-resistant C. coli is more prevalent than 
macrolide C. jejuni isolated from animals and human (6, 7, 27, 41). However, our results 
revealed that there appear to be no significant differences in the emerging frequencies of 
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erythromycin-resistant mutants between C. jejuni and C. coli under selection pressure. This 
was shown by both in vitro and in vivo experiments and suggested that C. coli is not 
intrinsically more mutable than C. jejuni to macrolides. The difference in the observed 
macrolide resistance rates between C. jejuni and C. coli isolated from food producing 
animals is probably related to the species of host animals and the production environments 
associated with the host animals. For example, C. coli is the predominant Campylobacter 
spp in pigs and turkeys (2, 21, 34, 39, 43), and macrolide is used as a growth promoter and 
therapeutic agent in the production of pigs and turkeys. In contrast, C. jejuni is predominant 
in broiler chickens, and macrolide is mainly used for therapeutic purpose. In addition, the 
production cycle for broilers is significantly shorter than that of turkeys or pigs, implying that 
broiler chickens are less exposed to antibiotics than turkeys and pigs. These differences in the 
residing animal hosts and the production environments may have contributed to the 
prevalence of macrolide-resistant C. coli in animal reservoirs. 
Gibreel et al. reported the A2074G mutation in a clinical C. jejuni isolate (14). This 
isolate exhibited a high level of erythromycin resistance, but the resistance was unstable after 
passage in antibiotic free media. Mutant RN14B E4-2 selected in this study (Table 2) had the 
same A2074G mutation, but the mutation did not occur on all of the three copies of the 23S 
rRNA gene in the mutant. This may explains why RN14B E4-2 has only a low-level 
resistance to erythromycin (MIC = 8 µg/ml). To our knowledge, this is the first report 
showing A2074G mutation occurrence in a laboratory C. coli strain related to macrolide 
resistance in Campylobacter. 
Recently the involvement of CmeABC efflux system in macrolide resistance has been 
examined by several research laboratories (8, 14, 31). It is a general notion that CmeABC is 
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linked to low and intermediate resistance to erythromycin, while the 23S rRNA mutations 
can confer a high level of erythromycin resistance (31, 36). Another most recent study 
concluded that 23S rRNA mutations and CmeABC work together in C. coli to confer high-
level macrolide resistance (8). In this study, the erythromycin-resistant mutants (except for 
RN14B E4-2) obtained by a single step selection did not have mutations at position 2074 or 
2075 of the 23SrRNA gene and had erythromycin MICs between 8 µg/ml and 256 µg/ml. 
Thus, the 23S rRNA mutation was not the major contributor for the acquired resistance in 
these strains. Notably, inactivation of cmeB in the mutants abolished their resistance to 
erythromycin (Table 3), indicating that CmeABC is a significant player in acquired 
resistance to erythromycin. Interestingly, immunoblotting using anti-CmeA, anti-CmeB and 
anti-CmeC antibodies revealed that CmeABC is not overexpressed in the macrolide-resistant 
mutants. 
In the in vivo treatment study, no erythromycin-resistant Campylobacter isolates were 
detected in the chickens treated with tylosin, suggesting that therapeutic use of tylosin in 
poultry has a low risk for promoting the occurrence of erythromycin-resistant Campylobacter . 
However, it should be pointed out that macrolide is also added in feed as a growth promoter. 
It is unknown at this stage if the constant presence of tylosin in feed affects the prevalence of 
macrolide-resistant Campylobacter. This possibility remains to be determined in future 
studies. Nevertheless, findings from this study revealed unique features associated with the 
development of macrolide resistance in Campylobacter and should facilitate the prudent use 
of antibiotics in animal production to avoid the selection of bacterial pathogens of public 
health concern. 
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Table 1. Frequency of the emergence of erythromycin-resistant Campyloabter in vitro 
under different selection pressure 
Erythromycin Frequency 
concentration 
S3B W7 RN14B MR32D 
4µg/ml 2.97± 3.22 xl0-9 <5.41 x10- 10 1.10±1.17 xl0-9 4.89±2.18 x10- 10 
8µg/ml 1.23±0.93 x10- 10 <5.41 x10- 10 5.56±2.53 x10- 10 4.50±1.65 x10- 10 
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Table 2. MI Cs of the mutants selected from the erythromycin-containing plates 
Mutant Background Erythromycin selection Mutation in MIC 
Pressure (µg/ml) 23sRNA (µg/ml) 
S3BE4-1 S3B 4 None 32 
S3BE4-2 S3B 4 None 32 
S3BE4-3 S3B 4 None 128 
S3BE8-1 S3B 4 None 256 
RN14BE4-1 RN14B 4 None 2 
RN14BE4-2 RN14B 4 A2074G 8 
RN14BE4-3 RN14B 4 None 32 
RN14BE8-1 RN14B 8 None 32 
RN14BE8-2 RN14B 8 None 32 
RN14BE8-3 RN14B 8 None 32 
MR32DE4-1 MR32D 4 None 8 
MR32DE8-1 MR32D 8 None 32 
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Table 3. Contribution of CmeABC to Macrolide resistance 
Strains 
S3B 
S3BE2-2 
S3BE2-2B 
RN14B 
RN14BE4-2 
RN14BE4-2B 
RN14BE4-3 
RN14BE4-3B 
description 
wild-type 
S3B derivative 
S3BE2-2 derivative (cmeB::Kan) 
wild-type 
RN14B derivative 
RN14BE4-2 derivative (cmeB::Kan) 
RN14B derivative 
RN14BE4-3 derivative (cmeB::Kan) 
Erythromycin MIC 
2µg /ml 
256µg /ml 
0.125µg /ml 
2µg /ml 
8µg /ml 
0.125µg /ml 
32µg /ml 
0.125µg /ml 
8 
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r/) 6 (\) 
(.) 
~ 5 bl) 
~ 4 (.) 
~ 
bl) 3 
..9 
C: 2 ro (\) 
~ 1 
0 
62 
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Days after initiation of tylosin treatment 
• W7-con 
• W7-trt 
~ S3B-con 
5l S3B-trt 
Fig. 1 Shedding levels (mean logl O cfu/g feces) of C. jejuni in colonized chickens before and 
after tylosin treatment. Each bar represents the arithmetic means ± standard error of the mean 
for 7-10 chickens. Birds in the treatment group received tylosin in drinking water (2 g/gallon) 
for three consecutive days, while control group was not treated with tylosin. 
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Fig. 2 Shedding level (mean loglO cfu/g feces) of C. coli in colonized chickens before 
and after tylosin treatment. Each bar represents the arithmetic means ± standard error of 
the mean for 2-10 chickens . Birds in the treatment group received in drinking water (2 
g/gallon) for three consecutive days, while control group was not treated with tylosin. 
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Fig. 3 Shedding level (mean loglO cfu/g feces) of C. jejuni in colonized chickens before 
and after multiple tylosin treatments . Each bar represents the arithmetic means ± 
standard error of the mean for 13-15 chickens. Birds in the treatment group received in 
drinking water (2 g/gallon) for three consecutive days for three times . The first tylosin 
treatment started on day 6 after inoculation. Second treatment was initiated on day 4 
after the first tylosin treatment. The third tylosin treatment started on day 4 after the 
second treatment. The control group was not treated with tylosin . 
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Fig. 4 Immunoblot analysis of CmeA, CmeB and CmeC production in S3B, S3B E2-2 and 
S3B E4-3 (erythromycin resistant isolates) (Lanes 2, 3, 4, respectively) . The same number of 
bacterial cells (based on optical density at 600 nm) was loaded in each lane. Prestained 
protein molecular mass markers (Bio-Rad) are shown in lane 1. The position of CmeA, 
CmeB and CmeC are as indicated. 
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CHAPTER 5. GENERAL CONCLUSIONS 
With the increasing antibiotic resistance rate of Campylobacter isolated from food-
producing animals, how to reduce or prevent the emergence of antibiotic resistant 
Campylobacter has become more and more important. Understandings of the factors 
influencing the emergence of antibiotic resistance and the antibiotic resistant mechanisms 
will help us to stop the spread of antibiotic-resistant Campylobacter. 
In this study we determined how the CmeABC efflux pump affects the emergence of 
FQ-resistant isolates, the emergence of erythromycin resistance in C. jejuni or C. coli in vitro 
and in vivo (in chickens) under selection pressures, and the genetic mechanism(s) responsible 
for macrolide resistance in these species. 
Our results indicate that inactivation of CmeABC reduced the emergence of FQ-
resistant mutants on high antibiotic concentrations, while over-expression of CmeABC 
resulted in an increase in the emerging frequency of FQ-resistant mutants and the resistance 
levels conferred by various types of gyrA mutations. These findings clearly indicate the role 
of CmeABC in the development of FQ-resistant Campylobacter and suggest that this efflux 
pump may be targeted to reduce development of FQ-resistance in Campylobacter. 
Plating of C. jejuni or C. coli culture on MH agar with or without erythromycin 
indicated that both Campylobacter species had a similar, but low rate of emergence 
frequency of erythromycin resistance in vitro (;:::::10- 10). Tylosin treatment of experimentally 
infected 3-day old broiler chickens (2g/gallon in drinking water for 3 days) with macrolide-
susceptible C. jejuni or C. coli strain, despite not killing all susceptible cells, did not promote 
the emergence oftylosin-resistant mutants. Sequencing of 23S rDNA genes revealed no point 
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mutation in the in vitro-selected mutants. CmeABC efflux pump was shown to be associated 
with both intrinsic and acquired macrolide resistance since inactivation of this pump (via 
allelic replacement) rendered Campylobacter far more susceptible to erythromycin as 
compared with the parent strains. Together, these results indicated the complexity of ecology 
of macrolide resistance in Campylobacter on farms and suggested that other factors other 
than therapeutic usage of macrolides may be involved in the emergence of resistance to these 
important antimicrobials in the animal reservoirs. Since macrolide antibiotics are also used 
for growth promotion, it will be interesting to find out if constant presence of macrolides in 
feed affects the emergence of erythromycin-resistant Campylobacter. This possibility 
remains to be examined in future studies. Findings from this study will facilitate the design of 
strategies to control the occurrence and transmission of antibiotic-resistant Campylobacter 
and promote the prudent use of antibiotics on poultry farms. 
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